Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 12/20 | 0.49 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | DGAT2 | Q96PD7 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16785016 | 0.95 | AOC3 (0.53) | AOC3SLC2A1ROCK2 | |
| SCHEMBL16785234 | 0.91 | AOC3 (0.49) | AOC3SLC2A1ROCK2ALDH1A1DGAT2 | |
| Cadaverine Tartrate SCHEMBL14992627 | 0.90 | AOC3 (0.51) | AOC3ROCK2 | |
| Cadaverine Tartrate SCHEMBL14992626 | 0.90 | AOC3 (0.51) | AOC3ROCK2 | |
| SCHEMBL16785258 | 0.89 | AOC3 (0.50) | AOC3SLC2A1ROCK2DGAT2KDM4E | |
| SCHEMBL16784930 | 0.89 | AOC3 (0.48) | AOC3SLC2A1ROCK2ALDH1A1KDM4E | |
| SCHEMBL16785276 | 0.87 | AOC3 (0.51) | AOC3SLC2A1ROCK2DGAT2KDM4E | |
| SCHEMBL12525457 | 0.86 | AOC3 (0.50) | AOC3SLC2A1ROCK2KDM4E | |
| SCHEMBL12526482 | 0.86 | AOC3 (0.51) | AOC3SLC2A1ROCK2 | |
| SCHEMBL12525786 | 0.85 | AOC3 (0.53) | AOC3SLC2A1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3002278-B1 | GUANIDINE COMPOUND | ASTELLAS PHARMA INC (JP) | 2017-04-19 | — | — | EP | disclosed |
| US-9556160-B2 | Guanidine compound | ASTELLAS PHARMA INC. (JP) | 2017-01-31 | — | — | US | disclosed |
| EP-2695881-B1 | GUANIDINE COMPOUND | ASTELLAS PHARMA INC (JP) | 2016-04-27 | — | — | EP | disclosed |
| EP-3002278-A1 | GUANIDINE COMPOUND | Astellas Pharma Inc. (JP) | 2016-04-06 | — | — | EP | disclosed |
| US-20150203480-A1 | GUANIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2015-07-23 | — | — | US | disclosed |
| US-9051283-B2 | Guanidine compound | ASTELLAS PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203480-A1 | GUANIDINE COMPOUND | GUCY1A1, VAPA, VAPB | AOC3 700/4885SLC2A1 129/4885ROCK2 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.